View Older Stories View More Recent Stories
-
Citius Oncology signs exclusive European distribution deal with Uniphar
-
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
-
Citius Pharmaceuticals launches cancer drug LYMPHIR following FDA approval
-
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
-
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
-
Citius Oncology closes $18 million stock offering at $1.09 per share
-
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
-
Citius Oncology raises $18 million in stock offering for LYMPHIR launch
-
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
-
Citius Oncology partners with Er-Kim for LYMPHIR distribution in Turkey, GCC
-
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
-
Citius Oncology launches LYMPHIR cancer treatment nationwide
-
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
-
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
-
Citius Oncology partners with Verix AI for LYMPHIR launch
-
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
-
Citius Pharmaceuticals closes $6 million direct offering
-
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
-
Citius Pharmaceuticals raises $6 million in registered direct offering
-
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
-
Citius Oncology signs distribution deal with McKesson for LYMPHIR launch
-
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
-
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
-
Citius Oncology partners with EVERSANA for LYMPHIR drug launch
-
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
-
Citius Oncology partners with Integris Pharma for LYMPHIR access in Europe
-
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
-
Citius Oncology closes $9 million equity offering
-
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
-
Citius Oncology prices $9 million offering at $1.75 per share
-
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
-
Citius Oncology (CTOR) Files $200M Mixed Shelf
-
Citius Oncology deploys AI platform ahead of LYMPHIR launch
-
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
-
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
-
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
-
Citius Oncology closes $9 million public offering
-
Citius Oncology Announces Closing of $9.0 Million Public Offering
-
Citius Oncology Announces Closing of $9.0 Million Public Offering
-
Citius Oncology prices $9 million public offering at $1.32 per share
-
Citius Oncology Announces Pricing of $9.0 Million Public Offering
-
Citius Oncology signs distribution deal with Cencora for LYMPHIR
-
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
-
Citius Pharmaceuticals regains Nasdaq compliance
-
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Citius Oncology (CTOR) Anticipates Commercial Launch of LYMPHIR in 2025
-
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
-
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
-
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
-
Citius Oncology (CTOR) stock soars on distribution deal
